There have been outstanding improvements in breast cancer treatment since the introduction of anti-HER2-targeted drugs such as monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and novel antibody–drug conjugates (ADCs) [2,3,4]. This evidence concerns the gene ERBB2 and breast carcinoma.